Nektar Therapeutics' Q4 earnings report exceeded analyst expectations in both EPS and sales, indicating a positive financial performance. The beat on both the top and bottom lines, coupled with a year-over-year sales increase, suggests a strong quarter for the company. This is likely to be viewed positively by investors, potentially leading to a short-term uptick in the stock price.